anxiolytic raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-09 and is reviewed periodically as new material appears.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
| Property | Value | Notes |
|---|---|---|
| Typical purity report | 95% or higher by HPLC | Area percentage at 214 nm |
| Identity confirmation | Mass spectrometry | Electrospray or MALDI |
| Powder storage | -20 C, desiccated | Protect from light |
| Solution storage | 2-8 C short term | Freeze aliquots for longer |
| Quality document | Certificate of analysis | States method and value |
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The properties of acids and bases are relevant to physical organic chemistry. Organic chemists are primarily concerned with Brønsted–Lowry acids/bases as proton donors/acceptors and Lewis acids/bases as electron acceptors/donors in organic reactions. Chemists use a series of factors developed from physical chemistry -- electronegativity/Induction, bond strengths, resonance, hybridization, aromaticity, and solvation—to predict relative acidities and basicities. The hard/soft acid/base principle is utilized to predict molecular interactions and reaction direction. In general, interactions between molecules of the same type are preferred. That is, hard acids will associate with hard bases, and soft acids with soft bases. The concept of hard acids and bases is often exploited in the synthesis of inorganic coordination complexes.
== Target and events == The primary target of the doctrine was originally the largest communist country, the Soviet Union. However, additional targets also included the other communist countries like the China, Laos, Vietnam, and North Korea. After the dissolution of the Soviet Union in 1991 and China's economic prominence in the early 21st century, China became the major target of the doctrine.
India Archived 11 January 2021 at the Wayback Machine. The World Factbook. Central Intelligence Agency. India web resources provided by GovPubs at the University of Colorado Boulder Libraries India from BBC News Wikimedia Atlas of India Geographic data related to India at OpenStreetMap Key Development Forecasts for India from International Futures
Sources: en.wikipedia.org
====== Interferons ====== Type I and type II interferons have anticancer activity (see the "Function" section in the "Interferon" article). Interferons can promote expression of major histocompatibility complex molecules, MHC I and MHC II, and stimulate immunoproteasome activity. All interferons drastically increase the presentation of MHC I dependent antigens. Interferon gamma (IFN-gamma) also strongly promotes the MHC II-dependent presentation of antigens. Higher MHC I expression leads to higher presentation of viral and abnormal peptides from cancer cells to cytotoxic T cells, while the immunoproteasome more efficiently processes these peptides for loading onto the MHC I molecule. Therefore, the recognition and killing of infected or malignant cells increases. Higher MHC II expression enhances presentation of viral and cancer peptides to helper T cells; which are releasing cytokines (such as more interferons, interleukins and other cytokines) that stimulate and co-ordinate the activity of other immune cells. By down regulation of angiogenic stimuli produced by tumor cells interferon can also suppress angiogenesis In addition, they suppress the proliferation of endothelial cells. Such suppression causes a decrease in tumor vascularization and subsequent growth inhibition. Interferons can directly activate immune cells including macrophages and natural killer cells. INF-1 and interferon gamma (IFN-γ) production are triggered by SeV molecular components in many cells (See "Virus-induced antiviral immunity" section above).
Birches native to Eurasia include Betula albosinensis – Chinese red birch (northern + central China) Betula alnoides – alder-leaf birch (China, Himalayas, northern Indochina) Betula ashburneri – (Bhutan, Tibet, Sichuan, Yunnan Provinces in China) Betula baschkirica – (eastern European Russia) Betula bomiensis – (Tibet) Betula browicziana – (Turkey and Georgia) Betula buggsii – (China) Betula calcicola – (Sichuan + Yunnan Provinces in China) Betula celtiberica – (Spain and Portugal) Betula chichibuensis – (Chichibu region of Japan) Betula chinensis – Chinese dwarf birch (China, Korea) Betula coriaceifolia – (Uzbekistan) Betula corylifolia – (Honshu Island in Japan) Betula costata – (northeastern China, Korea, Primorye region of Russia) Betula cylindrostachya – (Himalayas, southern China, Myanmar) Betula dahurica – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula delavayi – (Tibet, southern China) Betula ermanii – Erman's birch (eastern Siberia, Russian Far East, northeastern China, Korea, Japan) Betula falcata – (Tajikistan) Betula fargesii – (Chongqing + Hubei Provinces in China) Betula fruticosa – (eastern Siberia, Russian Far East, northeastern China, Mongolia, Korea, Japan) Betula globispica – (Honshu Island in Japan) Betula gmelinii – (Siberia, Mongolia, northeastern China, Korea, Hokkaido Island in Japan) Betula grossa – Japanese cherry birch (Japan) Betula gynoterminalis – (Yunnan Province in China) Betula honanensis – (Henan Province in China) Betula humilis or Betula kamtschatica – Kamchatka birch platyphylla (northern + central Europe, Siberia, Kazakhstan, Xinjiang, Mongolia, Korea) Betula insignis – (southern China) Betula karagandensis – (Kazakhstan) Betula klokovii – (Ukraine) Betula kotulae – (Ukraine) Betula luminifera – (China) Betula maximowicziana – monarch birch (Japan, Kuril Islands) Betula medwediewii – Caucasian birch (Turkey, Iran, Caucasus) Betula megrelica – (Republic of Georgia) Betula microphylla – (Siberia, Mongolia, Xinjiang, Kazakhstan, Kyrgyzstan, Uzbekistan) Betula nana – dwarf birch (northern + central Europe, Russia, Siberia, Greenland, Northwest Territories of Canada)) Betula pendula – silver birch (widespread in Europe and northern Asia; Morocco; naturalized in New Zealand and scattered locations in US + Canada) Betula platyphylla – (Betula pendula var. platyphylla) – Siberian silver birch (Siberia, Russian Far East, Manchuria, Korea, Japan, Alaska, western Canada) Betula potamophila – (Tajikistan) Betula potaninii – (southern China) Betula psammophila – (Kazakhstan) Betula pubescens – downy birch, also known as white, European white or hairy birch (Europe, Siberia, Greenland, Newfoundland; naturalized in scattered locations in US) Betula raddeana – (Caucasus) Betula saksarensis – (Khakassiya region of Siberia) Betula saviczii – (Kazakhstan) Betula schmidtii – (northeastern China, Korea, Japan, Primorye region of Russia) Betula sunanensis – (Gansu Province of China) Betula szechuanica – (Betula pendula var. szechuanica)—Sichuan birch (Tibet, southern China) Betula tianshanica – (Kazakhstan, Kyrgyzstan, Tajikistan, Uzbekistan, Xinjiang, Mongolia) Betula utilis – Himalayan birch (Afghanistan, Central Asia, China, Tibet, Himalayas) Betula wuyiensis – (Fujian Province of China) Betula zinserlingii – (Kyrgyzstan) Note: many American texts have B. pendula and B. pubescens confused, though they are distinct species with different chromosome numbers.
The four substrates of this enzyme are taxifolin, reduced nicotinamide adenine dinucleotide (NADH), oxygen, and a proton. Its products are dihydrogossypetin, oxidised NAD+, and water. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme is a flavin-containing monooxygenase that uses molecular oxygen as oxidant and incorporates one of its atoms into the starting material. The systematic name of this enzyme class is phenol,NADPH:oxygen oxidoreductase (2-hydroxylating). Other names in common use include phenol hydroxylase, and phenol o-hydroxylase. It uses flavin adenine dinucleotide as a second cofactor. The systematic name of this enzyme class is taxifolin,NAD(P)H:oxygen oxidoreductase (8-hydroxylating). This enzyme is also called taxifolin hydroxylase.
Sources: en.wikipedia.org
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.
Dry powder is kept frozen, desiccated, and shielded from light. Dissolved material is aliquoted and frozen to limit freeze-thaw cycles. Short-term refrigerated storage is common for working solutions.
Russia registers it as a prescription nasal product. Most other markets classify it as a research chemical with no approved medical use. Oversight of purity and labeling is consequently minimal in those markets.
Identity is confirmed by matching the retention time in reversed-phase chromatography against a reference standard and by measuring the molecular mass with mass spectrometry. Tandem mass spectrometry or amino acid analysis can verify the sequence of the seven residues. Because the peptide contains no aromatic amino acids, detection at 280 nm is not useful.